Participants | Dog response | RT-PCR (viral load) | Symptoms | Time between symptom onset and skin swab/between RT-PCR test and skin swab, days | Antibody test (time between RT-PCR test and antibody test), days | Comment | SARS-CoV-2 infection status (variant*, if available) |
VL1 | Negative | Positive (medium) | Fever, rhinitis, diarrhoea | 9/5 | Positive (33) | Close relative PCR positive | Positive (alpha) |
VL2 | Negative | Positive (medium) | Headache, cough, muscle pain | 4/3 | NA† | Relative and close contact PCR positive | Positive (alpha) |
VL3 | Negative | Positive (low) | Asymptomatic | NA/5 | NA | 6-year-old child. Two relatives PCR positive | Positive (wild-type)‡ |
VL4 | Negative | Positive (medium) | Fever, cough, loss of taste and smell, headache | 9/5 | Positive (48) | Relative PCR positive | Positive (alpha) |
VL5 | Negative | Positive (high) | Sore throat, headache fever | 0/0 | NA | 11-year-old-child. Four relatives PCR positive | Positive (NA) |
VL6 | Negative | Positive (medium) | Cough, muscle pain, loss of taste and smell, headache | 3/2 | NA | Two relatives PCR positive | Positive (alpha) |
VL7 | Negative | Positive (medium) | Aches, tiredness, headache | 3/2 | Positive (108) | Close contact with PCR positive | Positive (alpha) |
VL8 | Negative | Positive (medium) | Tiredness, sore throat, muscle pain, headache, loss of taste and smell, diarrhoea | 3/2 | NA | Close contact with PCR positive | Positive (alpha) |
VL9 | Positive | Negative | Asymptomatic | NA/0 | Positive (99) | Three PCR negative within 2 weeks | Possible positive |
VL10 | Positive | Negative | Asymptomatic | NA/3 | NA | NA | Uncertain |
VL11 | Positive | Negative | Asymptomatic | NA/3 | Negative (85) | Two PCR negative within 3 days | Negative |
VL12 | Positive | Negative | Asymptomatic | NA/0 | Negative (72) | Three PCR negative within 5 days | Negative |
VL13 | Positive | Negative | Asymptomatic | NA/0 | NA | PCR negative month after dog test. | Uncertain |
VL14 | Positive | Negative | Asymptomatic | NA/0 | NA | NA | Uncertain |
VL15 | Positive | Negative | Asymptomatic | NA/0 | NA | Two PCR tests negative within 3 days | Uncertain |
VL16 | Positive | Negative | Asymptomatic | NA/0 | Negative (82) | Three PCR negative tests within 3 days | Negative |
VL17 | Positive | Negative | Asymptomatic | NA/0 | Negative (95) | Two PCR negative tests within 3 days | Negative |
VL18 | Positive | Negative | Asymptomatic | NA/1 | Negative (83) | Two PCR positive | Negative |
VL19 | Positive | Negative | Headache, cough | NA/2 | Negative (68) | Negative |
*Variant, SARS-CoV-2 variant status was determined using S-Gene Target Failure, N501Y Mutation PCR and/or gene sequencing combined with epidemiological information (first alpha variant cases were detected 18 December in Finland).
†NA, not available.
‡Wild-type, refers to Wuhan like non-VoC lineages.
RT-PCR, reverse transcriptase-polymerase chain reaction.